Objective-Proteasome inhibitors used in the treatment of hematologic cancers also reduce thrombosis. Whether the proteasome participates in platelet activation or function is unclear because little is known of the proteasome in these terminally differentiated cells. Approach and Results-Platelets displayed all 3 primary proteasome protease activities, which MG132 and bortezomib (Velcade) inhibited. Proteasome substrates are marked by ubiquitin, and platelets contained a functional ubiquitination system that modified the proteome by monoubiquitination and polyubiquitination. Systemic MG132 strongly suppressed the formation of occlusive, platelet-rich thrombi in FeCl 3 -damaged carotid arteries. Transfusion of platelets treated ex vivo with MG132 and washed before transfusion into thrombocytopenic mice also reduced carotid artery thrombosis. Proteasome inhibition reduced platelet aggregation by low thrombin concentrations and ristocetin-stimulated agglutination through the glycoprotein Ib-IX-V complex. This receptor was not appropriately internalized after proteasome inhibition in stimulated platelets, and spreading and clot retraction after MG132 exposure also were decreased. The effects of proteasome inhibitors were not confined to a single receptor as MG132 suppressed thrombin-stimulated, ADP-stimulated, and lipopolysaccharide-stimulated microparticle shedding. Proteasome inhibition increased ubiquitin decoration of cytoplasmic proteins, including the cytoskeletal proteins Filamin A and Talin-1. Mass spectrometry revealed a single MG132-sensitive tryptic cleavage after R 1745 in an extended Filamin A loop, which would separate its actin-binding domain from its carboxy terminal glycoprotein Ibα-binding domain. 
P roteasome inhibitors are widely used for the treatment of hematologic cancers, specifically relapsed/refractory multiple myeloma and mantle cell lymphoma [1] [2] [3] ; however, little is known of their impact on platelet function and hemostasis. Potentially, these agents may also target platelets because a cyclic course of the proteasome inhibitor bortezomib (Velcade) induces significant cyclic thrombocytopenia, 4 and proteasome inhibition hastens platelet death and turnover. 5 Bortezomib therapy also associates with reduced thrombosis. 6, 7 Beyond this, there is little evidence of proteasome action on the platelet proteome, platelet activation, or thrombosis.
Platelets are recruited to the vascular wall at high shear through the glycoprotein Ib (GPIb)-IX-V receptor complex, 8 where the GPIbα subunit binds von Willebrand factor 9 and its C-terminal cytoplasmic domain interacts with the actinbinding protein Filamin A with high affinity. 10 This interaction tethers the receptor complex to the platelet cytoskeleton, maintaining the cytoskeletal architecture of resting platelets and those adhering in vessels at high shear rates. 11 The GPIbα subunit also contains a high-affinity binding site for thrombin that contributes to platelet activation when thrombin concentrations are low. 12 These interactions are essential for thrombosis. 13 Thrombotic platelet deposition is modeled in mice by FeCl 3 -induced injury of carotid arteries, 14, 15 resulting in rapid platelet adhesion and formation of an occlusive platelet-rich thrombus at the site of injury.
Nucleated cells remove proteins from their proteome by proteasome-catalyzed proteolysis. This multimeric complex consists of a 20S catalytic core of noncatalytic α-subunits and 3 distinct β-subunits that hydrolyze peptide bonds of unfolded protein substrates by β1 caspase-like hydrolysis, β2 tryptic hydrolysis, and β5 chymotryptic cleavage. [16] [17] [18] [19] The proteasome is capped by a 19S regulatory subunit that conducts substrate recognition, deubiquitination, unfolding, and protein translocation into the 20S core. 20, 21 Substrates for proteasome hydrolysis are recognized by the 19S core through the covalent conjugation of monomeric or polymeric chains of the ≈8 kDa ubiquitin to the targeted protein. [22] [23] [24] Newly released reticulated platelets express a richer proteome than older, dense platelets. 25 In addition, platelets contain several components of the 20S proteasome core [26] [27] [28] [29] and possess at least the chymotryptic activity of the proteasome. 30 Here, we show the expression of a functional ubiquitin/proteasome system in platelets. By investigating the impact of proteasome inhibition on a well-established mouse model of thrombosis and on a range of ex vivo activities, we conclusively demonstrate that the platelet proteasome contributes to cellular activation and function. Therapeutic proteasome inhibition in platelets produces a hypothrombotic state, but also might augment antiplatelet therapy.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

The Platelet Proteasome Aids Occlusive Thrombosis
Human platelets expressed all 3 primary proteolytic activities of the proteasome, effectively hydrolyzing peptides through chymotryptic, tryptic, and caspase-like cleavage ( Figure 1A ). The luminescent product was the same for each luminogenic proteasome substrate, so the caspase-like activity was ≈4-times more efficient than either the tryptic or the chymotryptic activity. The trimeric leucinyl proteasome inhibitor MG132 at 30 µmol/L completely blocked platelet chymotryptic and caspase-like activities and reduced the tryptic activity by half. MG132 at 30 µmol/L is just optimally inhibitory ( Figure I in the online-only Data Supplement). The structurally unrelated specific boron-based proteasome inhibitor, bortezomib, inhibited both chymotryptic and caspase-like activities but not the tryptic activity (not shown). Proteasome activity was retained in murine platelets that hydrolyzed these 3 substrates at equivalent ratios ( Figure I in the online-only Data Supplement).
We determined whether proteasome inhibition affected thrombosis by systemically injecting MG132 into BL6 mice to achieve an estimated initial circulating concentration of 30 µmol/L along with rhodamine dye to fluorescently label circulating platelets. We initiated occlusive thrombosis 15 minutes later in a surgically exposed external carotid artery by a brief ectopic application of 7.5% FeCl 3 . 14, 15 This oxidative insult to the vascular wall resulted in the deposition of fluorescently labeled platelets along the damaged vessel wall that increased over several minutes ( Figure 1B) . Typically, complete occlusion of the vessel occurred by 10 minutes after FeCl 3 treatment; however, in animals previously injected with MG132, occlusion was significantly delayed to 25 minutes ( Figure 1C ).
The delay in thrombosis after systemically administering MG132 need not solely reflect participation of platelet proteasomes in thrombosis. We therefore isolated and washed platelets from wild-type BL6 mice and treated these isolated cells with 30 µmol/L MG132 or buffer, washed the cells by centrifugation, and transfused these cells into mice previously rendered thrombocytopenic by γ irradiation. We induced carotid artery thrombosis with ectopic FeCl 3 as before and found that control platelets were fully functional and occluded the carotid artery by 10 minutes ( Figure 1D ). We again found occlusive thrombosis was delayed in mice reconstituted with platelets treated with MG132 ex vivo. Thus, the platelet proteasome participates in arterial thrombosis.
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Platelets Contain a Stimulatable Ubquitination System
Modification of platelet function by MG132 suggests that platelets may designate proteins as substrates for proteolysis by ubiquitination, as in nucleated cells. We determined whether platelets contained E1, E2, and E3 enzymes that sequentially conjugate ubiquitin to target proteins. To ensure that we assessed only platelet proteins, we also isolated highly purified, negatively selected platelets that were essentially free of nucleated cells (<1 monocyte in 10 9 platelets). 31 Western blotting showed that these platelets contained the E1 activating enzyme UBE1, E2, and E3 ligases, and Rpn2 and the 11S α-subunit of the 19S regulatory complex ( Figure 2A ).
We used in vitro ubiquitination of exogenous p53, because platelets lack this transcription factor, to determine whether platelet UBE1 was functional. Incubation of recombinant p53 with recombinant E1 and appropriate recombinant E2 and E3 enzymes along with ubiquitin and ATP resulted in robust p53 ubiquitination with the formation of numerous slowly migrating adducts ( Figure 2B ). Substitution of a platelet lysate for recombinant E1 also promoted in vitro ubiquitination of p53, although the higher-molecular-weight ladder was less prominent than produced by recombinant E1 ( Figure 2B ).
We next determined whether endogenous platelet proteins were modified by ubiquitin. Western blotting with FK2 antibody that recognizes both monoubiquitin and polyubiquitin chains showed that the proteome of quiescent cells contained multiple ubiquitinated proteins ( Figure 2C ). The intensity of ubiquitination increased after thrombin activation, although the pattern and position of the adducted bands was unaltered compared with control cells. ADP stimulation also increased ubiquitination of platelet proteins, but this primarily reflected an increase in modification of very slowly migrating proteins ( Figure 2C ). Platelets contain a functional ubiquitination system. A, Platelets contain components of ubiquitin-proteasome system. Immunoblots of platelet E1 activating enzyme, E2 and E3 conjugating enzymes, and proteasome regulatory cap proteins (n=3). B, Platelet E1 is functional. Platelet lysates substituted for recombinant E1 and together with recombinant E2, E3, ubiquitin, and ATP-ubiquitinated recombinant p53 (n=3). C, Agonist stimulation increases platelet proteome ubiquitination. Lysates of platelets stimulated with buffer, thrombin (thr), or ADP were immunoblotted with FK2 antibody against monoubiquitinated and polyubiquitinated proteins (n=3). D, MG132 increases proteome ubiquitination. Lysates of platelets, treated or not with MG132, were stimulated or not stimulated before immunoblotting with FK2 (n=3). E, MG132 increases polyubiquitination of platelet proteins (n=3). Western blotting of platelet lysates with FK1 antibody (n=3).
We investigated whether inhibiting the platelet proteasome altered the amount of ubiquitinated proteins. Pretreatment with MG132 increased both the abundance and the levels of ubiquitinated proteins as detected with the antiubiquitin antibody ( Figure 2D ). In fact, MG132 was significantly more effective than thrombin or ADP stimulation in enhancing decoration of the proteome with ubiquitin, and the combination of agonist stimulation and MG132 was not different from the effect of MG132 alone ( Figure 2D ). We observed a similar increase in ubiquitinated proteins after treatment with bortezomib (not shown). Probing the platelet proteome with FK1 antibody that recognizes only polyubiquitinated proteins revealed less abundant modification in unstimulated cells ( Figure 2E ). This was increased by agonist stimulation and was again greatly enhanced by MG132 treatment. Comparison of FK2 ( Figure 2D ) and FK1 ( Figure 2E ) immunoblots showed distinct patterns of monoubiquitination and polyubiquitination of the platelet proteome.
Filamin A Is Ubiquitinated, and Truncated by the Proteasome
Filamin A links the GPIb-IX-V complex to actin filaments of the cytoskeleton to modify cytoskeletal shape. 32 Filamin A was present in the soluble fraction of quiescent platelets as a 225-kDa fragment of the 280-kDa native protein ( Figure 3A ). MG132 inhibition of the proteasome decreased the amount of this smaller band and increased the amount of intact Filamin A. Capture of ubiquitinated platelet proteins by a sushi domain column followed by immunoblotting using anti-Filamin A antibody showed that the fragment of Filamin A in quiescent cells was constitutively modified with ubiquitin ( Figure 3B ). This approach also showed that MG132 increased the amount of Filamin A ubiquitination and increased the apparent size of the ubiquitinated Filamin A ( Figure 3B ). That Filamin A was ubiquitinated and that a larger, more extensively ubiquitinated protein accumulated after MG132 treatment was confirmed by the converse experiment in which Filamin A was immunoprecipitated from platelet lysates and then probed for ubiquitin ( Figure 3C ) using FK2 antibody.
The cytoskeletal protein Talin-1 participates in cell spreading, and similar experimental approaches of Western blotting ( Figure 3D ), sushi domain capture of ubiquitin adducts ( Figure 3E ), and immunoblotting of captured Talin-1 for monoubiquitin and polyubiquitin chains ( Figure 3F ) showed that Talin-1 was present in the cytosol in a rapidly migrating ubiquitinated form. Again, MG132 treatment increased its apparent size and ubiquitin content. Coomassie blue staining of soluble proteins showed that MG132 treatment did not alter overall platelet protein mass or composition, but there were 2 abundant exceptions ( Figure  3G ). Two new slowly migrating bands appeared in the soluble fraction of platelets treated with MG132. Mass spectrometry showed Filamin A to be present in the new band 1, and Talin-1 was present in bands 1 and 2 of the resolved soluble proteins (data not shown), corresponding to the altered mobility detected by Western blotting.
We used tandem mass spectrometry tags-chemically identical tags differentially substituted with heavy atoms that enable quantitative multiplexed analysis-to quantitatively compare the amount of Filamin A peptides in tryptic digests of control and MG132-treated platelets. Untreated (band 3) and MG132-treated (band 1) platelets were separately digested with trypsin, and their primary amines were exhaustively modified with isobaric tandem mass spectrometry tags (m/z 126 and m/z 127, respectively) before combined analysis by mass spectrometry. The peptides confirmed that both bands contained Filamin A, and the tags showed that the abundance of Filamin A tryptic peptides in band 1 and band 3 uniformly gave an m/z 126/127 ratio of 1.9. This ratio plunged to 0.08 after the tryptic peptide containing residues 1718 to 1745 ( Figure 3H ), demonstrating increased abundance of the full-length protein after MG132 treatment. Chymotryptic digestion of band 3 isolated from control cells generated a distinct peptide map, and selected reaction monitoring identified a new Filamin A peptide with S 1746 as its amino terminus (not shown). This identifies the R 1745 -S 1746 bond as the site of cleavage in control cells, which maps into the unfolded hinge 1 region of Filamin A ( Figure 3I ). Notably, this cleavage is tryptic-like and is distinct from the previously determined calpain cut site. 33 
Proteasome Inhibition Reduces Cytoskeleton-Dependent Functions
Filamin A is a critical regulator of cytoskeletal structure and function, so we next tested the hypothesis that proteasomal inhibition alters platelet functions regulated by cytoskeletal dynamics, including GPIb function, microparticle generation, and clot retraction.
First, we imaged cytoskeletal-dependent spreading by total internal reflection microscopy that detects only fluorophore closely opposed (≤200 nm) to a glass matrix. Calcein-labeled platelets adhered over time after activation by thrombin with extension of filopodia followed by lamellipodia (Movie in the online-only Data Supplement) that resulted in adherent spread cells ( Figure 4A ). In contrast, although MG132-treated cells adhered and spread after thrombin stimulation, they did so with less frequency and rapidity, and ultimately were less splayed ( Figure 4B ).
Stimulated platelets release prothrombotic microparticles from their surface that depend on cytoskeletal rearrangement after stimulation. 34 Thrombin induced a ≈6-fold increase in microparticle shedding ( Figure 4C and 4D) , which was significantly reduced by pretreating the platelets with either MG132 (Figure 4C ) or bortezomib ( Figure 4D ). MG132 also blocked microparticle release from ADP (not shown) or lipopolysaccharide-stimulated platelets ( Figure 4E ). The majority of these particles express phosphatidylserine that promotes thrombosis through tissue factor procoagulant activity ( Figure II in the online-only Data Supplement).
Cytoskeletal rearrangement retracts newly formed thrombi, promoting wound repair. 35, 36 Stimulation of platelets with thrombin induced rapid formation of a thrombus that then consolidated over time ( Figure 4F ). MG132 interfered with this process, ultimately decreasing retraction by 60%. 
Proteasome Inhibition Selectively Reduces Aggregation Stimulated by Low Concentrations of Thrombin
Thrombin stimulates platelets by cleaving surface proteaseactivated receptor 1 (PAR1) to create a self-stimulatory terminal SFLLRN peptide 37 ; however, at low concentrations, thrombin activates platelets through the high-affinity GPIb-IX-V receptor. 12 Both MG132 and bortezomib reduced homotypic platelet aggregation at low concentrations of thrombin ( Figure 5A ).
The effect of proteasome inhibitors was on the high-affinity GPIb-IX-V complex because the SZ2 antibody against GPIbα (CD42b) fully blocked aggregation at a low concentration of thrombin ( Figure 5A ). The PAR1 agonist SFLLRN induced platelet aggregation that was completely blocked by a PAR1-specific antagonist (RWJ56110; Figure 5B ). However, neither MG132 ( Figure 5B ) nor bortezomib (not shown) suppressed aggregation induced by SFLLRN. Aggregation induced by a low submaximal amount of SFLLRN also was unimpeded by MG132 ( Figure IV in the online-only Data Supplement). Thus, the inhibition observed at low thrombin concentration by proteasome inhibitors is independent of PAR1. MG132 also failed to affect aggregation induced by AYPGFK stimulation of PAR4 ( Figure IV in the online-only Data Supplement). Furthermore, neither MG132 nor bortezomib inhibited platelet aggregation stimulated by a higher thrombin concentration that acts through PAR1 ( Figure 5C ). The modifiers SZ2, MG132, RWJ56110, or bortezomib (not shown) by themselves did not induce aggregation ( Figure 5D ).
Proteasome protease activity was required by the highaffinity thrombin receptor because epoxomicin inhibited platelet aggregation by low thrombin concentrations but not by high thrombin concentrations that stimulate PAR1 ( Figure  V in the online-only Data Supplement). Epoxomicin is a fungal metabolite, structurally unrelated to either MG132 or bortezomib, that specifically inhibits proteasome protolysis without inhibiting calpain, trypsin, chymotrypsin, or cathepsin B at concentrations 50-times higher than we used for blocking platelet aggregation. 38 The GPIb-IX-V complex is displayed on the surface of quiescent cells and is downregulated after thrombin stimulation. 39 We found that both MG132 ( Figure 5E ) and bortezomib ( Figure 5F ) stabilized the GPIb-IX-V complex on the surface of stimulated cells and enhanced surface GPIbα (CD42b) expression. Ristocetin increases the affinity of GPIbα for von Willebrand factor, agglutinating unactivated cells, and pretreatment of quiescent platelets with MG132 ( Figure 5G ) or bortezomib ( Figure 5H ) reduced ristocetininduced and botrocetin-induced (not shown) platelet agglutination. Thus, despite the increased surface expression of the GPIb-IX-V complex after proteasome inhibition, the complex is less able to interact with von Willebrand factor than in control platelets.
Discussion
Multiple myeloma is associated with an increased incidence of venous [40] [41] [42] and arterial 43 thrombotic disease, and bortezomib therapy suppresses these thrombotic states. 7 Platelets display proteasome chymotryptic activity that is greatly stimulated by soluble agonists. 30 Additionally, bortezomib represses ADPinduced aggregation, 27 and platelets isolated from patients receiving bortezomib are hyporesponsive to other stimuli. 6, 7 A second proteasome inhibitor, PSI, suppresses thrombosis in hypertensive animals. 44 We extend these observations by showing that platelets contain an intact and functional ubiquitin/proteasome system that participates in agonist-stimulated responses, especially those aided by cytoskeletal rearrangement. We found that inhibition of the proteolytic activity of the proteasome reduced thrombosis at sites of oxidative damage to murine carotid arterial walls. Because MG132 was introduced into the circulation in this experiment, protection need not have been a direct effect of MG132 on platelet function, but the target of MG132 in platelet is in fact the proteasome. We treated purified platelets with MG132 ex vivo, washed them, and transfused these cells into mice rendered thrombocytopenic by previous γ irradiation. This platelet-specific exposure to MG132 interfered with the in vivo function of platelets because MG132-treated platelets were deficient in their occlusion of a FeCl 3 -damaged carotid artery. Remarkably, this ex vivo exposure exactly mimicked systemic exposure to MG132. This establishes a role for the platelet proteasome in thrombosis.
Platelets contained a functional ubiquitin system that modified cellular proteins to mark them as proteasome substrates. The proteome of quiescent platelets contained numerous ubiquitin-protein conjugates whose adduction was increased on stimulation, consistent with the previous observation that collagen activation stimulates ubiquitination of platelet Syk kinase 45 through the E3 ligase Cbl-b. 46 Two of the proteins decorated with ubiquitin in quiescent platelets were Filamin A and Talin-1. Agonist stimulation modestly increased the amount of ubiquitin esterified in the platelet proteome, but blockade of the proteasome was far more effective than agonist stimulation for this, with the result that heavily ubiquitinated Filamin A and Talin-1 accumulated in the cytoplasm of cells with diminished proteasome proteolytic activity.
Filamin A is organized into an actin-binding domain, 24 tightly compacted 4.1, ezrin, radixin, moesin immunoglobulinlike repeats connected with short linking sequences, and 2 unstructured hinge regions. Cytoplasmic Filamin A migrated more quickly than the intact protein during gel electrophoresis, suggesting that it primarily was a fragment. Quantitative comparison of tryptic peptides using tandem mass spectrometry tags showed that MG132 protected Filamin A from cleavage to the smaller 225-kDa fragments. Identification of Filamin A peptides present only after MG132 treatment and identification of the new amino terminal peptide after chymotryptic digestion by multiple reaction monitoring showed that cleavage of the Filamin A protein occurred between R1745 and S1746. This is in a hinge region that is not compacted into FERM domains. Cleavage at this site is distinct from the previously determined calpain cut site 33 and shows that the protease was tryptic because it occurred after an arginine residue. The proteasome subunits functionally interact with one another 47 to degrade proteins to amino acids and small peptides, but the proteasome also processes large proteins to functional fragments, as shown by nuclear factor-κB p105 proteolysis to the p50 transcription factor. 48 We now identify the longer unstructured Filamin A loop as another site of limited proteasome proteolysis, but our result is associative so we cannot ascribe this proteolysis as causal in MG132 inhibition of platelet adhesion or spreading.
Platelets pretreated with MG132 or bortezomib aggregated less in response to low concentrations of thrombin. Adhesion, spreading, microparticle shedding, and the ability to generate the force to retract formed clots were also reduced by proteasome inhibition. Cytoskeletal interactions aid microparticle shedding from stimulated platelets, and proteolysis by Figure 5 . MG132 reduces aggregation in response to low-dose thrombin and prevents glycoprotein Ibα (GPIbα) downregulation. A, MG132 and bortezomib suppress platelet aggregation induced through the high-affinity thrombin receptor, GPIb-IX-V. Aggregation induced by 0.025 U thrombin (thr) was reduced by MG132 and bortezomib (n=3). B, MG132 failed to reduce aggregation stimulated by the protease-activated receptor 1 (PAR1) agonist peptide SFLLRN (n=3). C, Neither MG132 nor bortezomib blocks aggregation from thrombin activation of PAR1. Platelet aggregation by 0.1 U thrombin with or without SZ2 antibody (n=3). D, GPIbα or PAR1 inhibition alone does not induce aggregation (n=3). E, MG132 repressed stimulated GPIbα downregulation. Flow cytometry of surface CD42b (GPIbα) expression on platelets treated or not treated with MG132 and stimulated or not stimulated with 0.025 U thrombin (n=3). F, Bortezomib repressed surface GPIbα downregulation. Flow cytometry of GPIbα expression on control and thrombin-stimulated platelets (n=3). G, MG132 suppressed ristocetin-induced agglutination. Quiescent platelets pretreated or not pretreated with MG132 were agglutinated with ristocetin (n=3). H, Bortezomib suppressed ristocetin-induced agglutination. Quiescent platelets pretreated or not pretreated with bortezomib were agglutinated with ristocetin (n=3). activated calpain 49, 50 and caspase-3 51 promotes microparticle shedding through cytoskeletal proteolysis. 50 The reduction of microparticle shedding is additionally revealing because MG132 suppressed shedding after stimulation by lipopolysaccharide activation of Toll-like receptor 4, thrombin activation of PAR1, and ADP activation of P2Y12. So, MG132 interference with stimulated platelet function is not restricted to GPIb-IX-V activation by thrombin.
We establish that platelets, like nucleated cells, express a functional ubiquitin/proteasome system that enables them to ubiquitinate their proteome. This decoration increases on stimulation and modulates an array of responses from several receptors that all engage the cytoskeleton. The cytoskeletal proteins Filamin A and Talin-1 are targets of ubiquitination and proteasome-mediated proteolysis. The ubiquitin/proteasome system of platelets affects their response to thrombotic stimuli, and proteasome inhibition effectively delayed arterial thrombosis. Bortezomib is already in clinical practice for multiple myeloma and mantle cell lymphoma, so elucidation of its antiplatelet activity defines a new salutary function of these inhibitors.
